Psyence Biomedical Ltd cash flow statement PBMWW

Annual Quarterly

In fiscal 2025, which ended Mar 31, 2025, Psyence Biomedical Ltd used $3.7 million of cash from operations, down 26.8% from the year before. It spent $9,877 on capital expenditures. Free cash flow was negative, at -$3.7 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

FY 2025
Mar 31, 2025
FY 2024
Mar 31, 2024
Operating
Operating cash flow
-4
-26.8%
-3
Investing
Capital expenditures
0
+72.5%
0
Investing cash flow
-0
-183.4%
-0
Financing
Debt issued
1
—
Debt repaid
—
0
Financing cash flow
9
+289.5%
2
Change in cash
Net change in cash
5
+998.7%
-1
Free cash flow
-4
-26.9%
-3
Per share
Free cash flow per share
-19.40
+92.8%
-270.67
Ratios
Cash conversion
-3.69x
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PBM (Nasdaq), PBMWW (Nasdaq)
Fiscal year ends
March 31
Incorporated in
Ontario, Canada
Headquarters
Toronto
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1985062

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.